Jpmorgan Chase & CO 2seventy Bio, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 27,765 shares of TSVT stock, worth $138,825. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,765
Previous 482,204
94.24%
Holding current value
$138,825
Previous $1.42 Million
90.33%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding TSVT
# of Institutions
27Shares Held
8.43MCall Options Held
91.9KPut Options Held
0-
Black Rock Inc. New York, NY3.66MShares$18.3 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY1MShares$5.01 Million1.94% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL104KShares$518,2400.0% of portfolio
-
Nuveen, LLC Charlotte, NC93.1KShares$465,5750.0% of portfolio
-
Colony Group LLC Boston, MA53.3KShares$266,3750.0% of portfolio
About 2seventy bio, Inc.
- Ticker TSVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,873,600
- Market Cap $189M
- Description
- 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...